The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 59-67

  Calvier, Laurent ^a   Martinez Martinez, Ernesto ^b,c   Miana, Maria ^b   Cachofeiro, Victoria ^b   Rousseau, Elodie ^a   Sádaba, J Rafael ^c,d   Zannad, Faiez ^a,e,f   Rossignol, Patrick ^a,e,f   López Andrés, Natalia ^a,c  

^a INSERM UMR S 1116 University of Lorraine   (France)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Atención Primaria Y Promoción de La Salud   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f F CRIN INI CRCT (Cardiovascular and Renal Clinical Trialists)   (France)

Author keywords

Aldosterone; Biomarker; Cardiorenal injury; Collagen; Galectin 3

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; GALECTIN 3; MESSENGER RNA; PECTIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HEART INJURY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INJURY; KNOCKOUT MOUSE; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; TREATMENT OUTCOME; TUBULAR DYSFUNCTION; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; WISTAR RAT;

ACUTE KIDNEY INJURY; ALDOSTERONE; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTIN 3; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; SPIRONOLACTONE;

EID: 84920268893     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.08.002     Document Type: Article

References (22)

1. Rogerson F.M., Fuller P.J. Mineralocorticoid action. Steroids 2000, 65:61-73.
2. López-Andrés N., Martin-Fernandez B., Rossignol P., et al. Arole for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 2011, 301:H2372-H2382.
3. Briet M., Schiffrin E.L. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6:261-273.
4. Cachofeiro V., Miana M., de Las Heras N., et al. Aldosterone and the vascular system. JSteroid Biochem Mol Biol 2008, 109:331-335.
5. Bunda S., Wang Y., Mitts T.F., et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. JBiol Chem 2009, 284:16633-16647.
6. Wei J., Li Z., Ma C., et al. Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. Cell Biol Int 2013, 37:725-730.
7. Lekawanvijit S., Kompa A.R., Wang B.H., Kelly D.J., Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res 2012, 111:1470-1483.
8. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635.
9. Glinsky V.V., Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res 2009, 344:1788-1791.
10. Kim H., Lee J., Hyun J.W., Park J.W., Joo H., Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007, 31:655-662.
11. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
12. Wan S.Y., Zhang T.F., Ding Y. Galectin-3 enhances proliferation and angiogenesis of endothelial cells differentiated from bone marrow mesenchymal stem cells. Transplant Proc 2011, 43:3933-3938.
13. Kolatsi-Joannou M., Price K.L., Winyard P.J., Long D.A. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE 2011, 6:e18683.
14. Papaspyridonos M., McNeill E., de Bono J.P., et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008, 28:433-440.
15. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
16. Lopez-Andrès N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
17. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAm Heart Assoc 2012, 1:e000760.
18. De Boer R.A., Lok D.J.A., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
19. Colnot C., Fowlis D., Ripoche M.A., Bouchaert I., Poirier F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn 1998, 211:306-313.
20. Paulus W.J., Tschöpe C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heartfailure with normal left ventricular ejection fraction by the Heart Failure and EchocardiographyAssociations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
21. Yu L., Ruifrok W.P.T., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
22. Bichara M., Attmane-Elakeb A., Brown D., et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology 2006, 16:36-45.